Replacement therapy in pregnant women with von Willebrand disease during delivery: Factor levels and pharmacokinetics by Wala Al Arashi, Michael E. Cloesmeijer, Frank W. G. Leebeek, Johannes J. Duvekot, Marieke J. H. A. Kruip, Ron A. A. Mathôt, Marjon H. Cnossen, the OPTI‐CLOT/To WiN study group and SYMPHONY consortium

Get full text

Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease by Johan Boender, Ferdows Atiq, Marjon H. Cnossen, Johanna G. van der Bom, Karin Fijnvandraat, Joke de Meris, Moniek P. M. de Maat, Karin P. M. van Galen, Britta A. P. Laros-van Gorkom, Karina Meijer, Jeroen Eikenboom, Frank W. G. Leebeek, for the WiN study group*

Get full text

Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype by Ferdows Atiq, Johan Boender, Waander L. van Heerde, Juan M. Tellez Garcia, Selene C. Schoormans, Sandy Krouwel, Marjon H. Cnossen, Britta A. P. Laros-van Gorkom, Joke de Meris, Karin Fijnvandraat, Johanna G. van der Bom, Karina Meijer, Karin P. M. van Galen, Jeroen Eikenboom, Frank W. G. Leebeek, for the WiN Study Group*

Get full text